Stanford Cancer Institute


Showing 31-40 of 43 Results

  • Matthew Bogyo

    Matthew Bogyo

    Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsOur lab uses chemical, biochemical, and cell biological methods to study protease function in human disease. Projects include:

    1) Design and synthesis of novel chemical probes for serine and cysteine hydrolases.

    2) Understanding the role of hydrolases in bacterial pathogenesis and the human parasites, Plasmodium falciparum and Toxoplasma gondii.

    3) Defining the specific functional roles of proteases during the process of tumorogenesis.

    4) In vivo imaging of protease activity

  • Melissa L Bondy

    Melissa L Bondy

    Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by courtesy, of Pediatrics

    Current Research and Scholarly InterestsPrincipal Investigator, Discovery, Biology and Risk of Inherited Variants in Glioma, 1R01CA217105-01A1, NIH/NCI, 05/01/2018-06/30/2022, MPI (Contact PI)

    Principal Investigator, Characterizing Germline and Somatic Alterations by Glioma Subtypes and Clinical Outcome, 1R01CA232754-01, 07/01/2019-06/30/2023, MPI (Contact PI)

    Co-Leader (Project), SPORE in Brain Cancer, PI – Fred Lang (Sub with MD Anderson), 2 P50CA127001-11, 09/01/2019-08/31/2023

    Co-Investigator, Stanford University Cancer Center, PI – Steve Artandi, P30 CA124435, NCI, 09/15/10-05/31/22

    Co-Investigator, Ovarian Cancer Survival in African-American Women, PI, Joellen Schildkraut, R01 CA237318-01A1, NIH/NCI, 07/01/2020-06/31/2025

  • Donna M. Bouley, DVM, PhD

    Donna M. Bouley, DVM, PhD

    Professor of Comparative Medicine at the Stanford University Medical Center, Emerita

    Current Research and Scholarly InterestsResearch interests: ocular pathology, host-pathogen interactions in infectious disease, infectious disease in frogs, phenotypic characterization of tg and ko mice, histopathology of minimally-invasive radiological ablation techniques (focused ultrasound, cryoablation).

  • Linda Boxer, MD, PhD

    Linda Boxer, MD, PhD

    Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor

    Current Research and Scholarly InterestsRegulation of expression of oncogenes in normal and malignant hematologic cells.

  • Scott D. Boyd, MD PhD

    Scott D. Boyd, MD PhD

    Stanford Professor of Food Allergy and Immunology and Professor of Pathology

    Current Research and Scholarly InterestsOur goal is to understand the lymphocyte genotype-phenotype relationships in healthy human immunity and in immunological diseases. We apply new technologies and data analysis approaches to this challenge, particularly high-throughput DNA sequencing and single-cell monoclonal antibody generation, in parallel with other functional assays.

  • Onn Brandman

    Onn Brandman

    Associate Professor of Biochemistry and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsThe Brandman Lab studies how cells sense and respond to stress. We employ an integrated set of techniques including single cell analysis, mathematical modeling, genomics, structural studies, and in vitro assays.

  • James D. Brooks

    James D. Brooks

    Keith and Jan Hurlbut Professor

    Current Research and Scholarly InterestsWe use genomic approaches to identify disease biomarkers. We are most interested in translating biomarkers into clinical practice in urological diseases with a particular focus in cancer.

  • Martin Brown

    Martin Brown

    Professor of Radiation Oncology, Emeritus

    Current Research and Scholarly InterestsWe seek to understand the mechanisms responsible for the resistance of cancers to treatment and to develop strategies to overcome these resistances. We are using molecular and cellular techniques and mouse models to potentiate the activity of radiation on tumors by inhibiting the bone marrow rescue of the tumor vasculature following therapy.

  • Anne Brunet

    Anne Brunet

    Michele and Timothy Barakett Endowed Professor

    Current Research and Scholarly InterestsWe want to understand aging based on the integration of model organisms with diverse lifespans. We have identified pathways involved in delaying aging in response to external stimuli such as availability of nutrients. We are also interested in addressing complex questions about aging in vertebrates, focusing on brain aging and rejuvenation. Finally, we have pioneered the short-lived African killifish as a powerful model to identify new principles of vertebrate aging and ‘suspended animation’.

  • Nam Quoc Bui

    Nam Quoc Bui

    Clinical Associate Professor, Medicine - Oncology

    BioDr. Bui is a Clinical Associate Professor of Medicine at the Stanford Cancer Institute and a specialist in Sarcoma. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data.

    He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to medical students, residents, and oncology fellows. Dr. Bui is the founding Editor-in-Chief of the journal “Current Problems in Cancer: Case Reports”, an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer. He also serves as the Chair of the Data Safety Monitoring Committee at the Stanford Cancer Institute, overseeing the board that reviews all investigator-initiated cancer trials run at Stanford.